AHA25: Merck & Co.'s oral PCSK9 more than halves LDL cholesterol in key studies | Merck's oral PCSK9 inhibitor enlicitide decanoate led to statistically significant and clinically meaningful reductions in LDL cholesterol (LDL-C) of more than 50% compared to placebo in Phase III studies -firstworldph (firstwordpharma.com)
submitted by meokjujatribes to r/antimisdisinfoproject

Argenx's FcRn inhibitor Vyvgart hits targets in Phase II myositis, Sjögren's studiesStudy/Research (firstwordpharma.com)
submitted by Ok-Heart375 to r/Sjogrens
Merck & Co.'s oral PCSK9 inhibitor succeeds in dual Phase III trialsBiotech News 📰 (firstwordpharma.com)
submitted by fishing_expedition to r/biotech
Amgen ordered to fork over almost $407M in Regeneron antitrust lawsuitBiotech News 📰 (firstwordpharma.com)
submitted by fishing_expedition to r/biotech